Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Oct 20, 2009


Illumina has launched cBot, a new instrument for clonal amplification of sequencing libraries for the Genome Analyzer. The system, which uses pre-packaged reagents, allows users to perform clonal amplification in four hours with less than ten minutes of hands-on time, according to the company.

Correlagen Diagnostics has launched its CardioGeneScan test, a comprehensive genetic test for the diagnosis of familial cardiac disease. The commercial test runs on the Helicos Genetic Analysis system, although it can also be performed on the Illumina Genome Analyzer platform, Correlagen CEO David Margulies told In Sequence via e-mail.

CardioGeneScan tests for disease-causing variation in all genes known to be associated with familial cardiovascular diseases, including cardiomyopathy, arrhythmia, thoracic aortic aneurysm, Noonan Syndrome and related diseases, and early-onset coronary artery disease.

Correlagen said that as associations with inherited cardiac disease are demonstrated by researchers and clinicians, the company will add new genes to the test. In addition, result reports will be revised periodically as new knowledge becomes available about the genetics of cardiac disease that impacts the clinical interpretation of previously identified variants.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.